CBIO vs COP · $491.3M cap vs P/E 19, rev $58.94B
Crescent Biopharma, Inc. (CBIO) versus ConocoPhillips (COP) — a side-by-side from cached financials, not a winner call.
Crescent Biopharma, Inc. (CBIO) is a biotechnology company listed on NASDAQ.
ConocoPhillips (COP) is a oil & gas e&p company listed on NYSE. It is led by Ryan Lance.
CBIO does not have a complete income-statement cache yet.
Latest reported COP revenue for 2025-12-31 was $58.94B. Net income was $7.99B. Revenue was up 7.7% from 2024-12-31 to 2025-12-31. COP currently screens at market cap $135.49B and trailing P/E 18.8.
CBIO currently screens at market cap $491.3M. COP currently screens at market cap $135.49B and trailing P/E 18.8.
Not investment advice. Open the CBIO and COP stock pages for the full models.
Not investment advice.